Anixa Biosciences Inc (ANIX) 10-K Annual Report Thu Jan 09 2020

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Oct. 31, 2019	Jan. 08, 2020	Apr. 30, 2019
Document Information Line Items
Entity Registrant Name	Anixa Biosciences Inc
Document Type	10-K
Current Fiscal Year End Date	--10-31
Entity Common Stock, Shares Outstanding		20,821,204
Entity Public Float			$ 72,311,537
Amendment Flag	false
Entity Central Index Key	0000715446
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Oct. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Ex Transition Period	false
Entity Interactive Data Current	Yes

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/715446/000151316220000009/form10k.htm

View differences made from one year to another to evaluate Anixa Biosciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Anixa Biosciences Inc.

Continue

Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy

Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter by Sentiment:

All

Positive

Negative

Filter by Category:

All

Revenue

Financial

Other

Filter by Subcategory:

All

Product

Expense

Cash Flow

Other

Inside Anixa Biosciences Inc's 10-K Annual Report:

Revenue - Product Highlight
Cash provided by financing activities was approximately $5,734,000, resulting from the sale of 1,363,872 shares of common stock in an at-the-market equity offering of approximately $5,527,000, the proceeds from exercise of stock options of approximately $122,000, the proceeds from settlement of a shareholder derivative complaint of approximately $45,000 and the proceeds from the sale of common stock pursuant to employee stock purchase plan of approximately $39,000.

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits

Exhibit 3.8: Articles Of Incorporation

Exhibit 21: Subsidaries Of The Registrant

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: ANIX
CIK: 715446
Form Type: 10-K Annual Report
Accession Number: 0001513162-20-000009
Submitted to the SEC: Thu Jan 09 2020 4:16:35 PM EST
Accepted by the SEC: Thu Jan 09 2020
Period: Thursday, October 31, 2019
Industry: Medical Laboratories

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/anix/0001513162-20-000009.htm

Anixa Biosciences Inc (ANIX) SEC Filing 10-K Annual report for the fiscal year ending Thursday, October 31, 2019

SEC Filings

ANIX Valuations

ANIX Annual Reports

ANIX Quarterly Reports

ANIX Corporate News